The global Inhalation CDMO market is projected to grow from US$ 3154 million in 2024 to US$ 6564 million by 2031, at a CAGR of 11.2% (2025-2031), driven by critical product segments and diverse end‑use applications.

Inhalation CDMO Market

Inhalation CDMO (Contract Development and Manufacturing Organization) refers to specialized companies that provide end-to-end services in the development and manufacturing of inhalable drugs and therapies. These organizations work with pharmaceutical companies to design, develop, test, and produce inhalation products, such as metered-dose inhalers, dry powder inhalers, and nebulizers. The services offered by inhalation CDMOs typically include formulation development, analytical testing, device engineering, clinical trial manufacturing, and large-scale commercial production. By leveraging their expertise, CDMOs help bring inhalation therapies to market more efficiently and with greater compliance to regulatory standards.

Inhalation Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers that assist pharmaceutical companies in the development and production of inhalation products, such as inhalers and nebulizers. The market for inhalation CDMOs is growing steadily, driven by the increasing prevalence of respiratory diseases like asthma and COPD, and the rising demand for complex inhalation therapies. The North America and Europe are the major sales regions, although significant growth is also expected in Asia-Pacific. Market opportunities lie in the development of novel drug delivery systems, biologics, and personalized medicine, while challenges include regulatory complexities and the high cost of development. Future product trends point towards the integration of digital health technologies and sustainable packaging solutions in inhalation products.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Inhalation CDMO market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Inhalation CDMO Market Report

Report Metric	Details
Report Name	Inhalation CDMO Market
Accounted market size in 2024	US$ 3154 million
Forecasted market size in 2031	US$ 6564 million
CAGR	11.2%
Base Year	2024
Forecasted years	2025 - 2031
Segment by Type	Metered Dose Inhalers (MDIs) Dry Powder Inhalers (DPIs) Soft Mist Inhalers (SMIs) Others
Segment by Application	Commercial Academic Research Others
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, Vectura, Iconovo, CritiTech, Hovione, Recipharm, Aptar Pharma, Kindeva, Sanner, Particle Sciences, Experic, Enteris Biopharma, Catalent, HCmed, Ritedose, Bespak, Proveris, Bend Bioscience, Renejix
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Inhalation CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is Inhalation CDMO Market growing?

Ans: The Inhalation CDMO Market witnessing a CAGR of 11.2% during the forecast period 2025-2031.

What is the Inhalation CDMO Market size in 2031?

Ans: The Inhalation CDMO Market size in 2031 will be US$ 6564 million.

Who are the main players in the Inhalation CDMO Market report?

Ans: The main players in the Inhalation CDMO Market are Lonza, Vectura, Iconovo, CritiTech, Hovione, Recipharm, Aptar Pharma, Kindeva, Sanner, Particle Sciences, Experic, Enteris Biopharma, Catalent, HCmed, Ritedose, Bespak, Proveris, Bend Bioscience, Renejix

What are the Application segmentation covered in the Inhalation CDMO Market report?

Ans: The Applications covered in the Inhalation CDMO Market report are Commercial, Academic Research, Others

What are the Type segmentation covered in the Inhalation CDMO Market report?

Ans: The Types covered in the Inhalation CDMO Market report are Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Soft Mist Inhalers (SMIs), Others

1 Study Coverage

1.1 Introduction to Inhalation CDMO: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Inhalation CDMO Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Metered Dose Inhalers (MDIs)

1.2.3 Dry Powder Inhalers (DPIs)

1.2.4 Soft Mist Inhalers (SMIs)

1.2.5 Others

1.3 Market Segmentation by Application

1.3.1 Global Inhalation CDMO Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Commercial

1.3.3 Academic Research

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Inhalation CDMO Revenue Estimates and Forecasts 2020-2031

2.2 Global Inhalation CDMO Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020-2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

3.1 Global Inhalation CDMO Player Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2020-2025)

3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Player (2020 VS 2024)

3.2 Global Inhalation CDMO Companies Headquarters and Service Footprint

3.3 Main Product Type Market Size by Players

3.3.1 Metered Dose Inhalers (MDIs) Market Size by Players

3.3.2 Dry Powder Inhalers (DPIs) Market Size by Players

3.3.3 Soft Mist Inhalers (SMIs) Market Size by Players

3.3.4 Others Market Size by Players

3.4 Global Inhalation CDMO Market Concentration and Dynamics

3.4.1 Global Market Concentration (CR5 and HHI)

3.4.2 Entrant/Exit Impact Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Inhalation CDMO Revenue Trends by Type

4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.1.2 Global Revenue Market Share by Type (2020-2031)

4.2 Key Product Attributes and Differentiation

4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.3.1 High-Growth Niches and Adoption Drivers

4.3.2 Profitability Hotspots and Cost Drivers

4.3.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Inhalation CDMO Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.1.2 Revenue Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2020-2031)

6.2 North America Key Players Revenue in 2024

6.3 North America Inhalation CDMO Market Size by Type (2020-2031)

6.4 North America Inhalation CDMO Market Size by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Inhalation CDMO Market Size by Country

6.6.1 North America Revenue Trends by Country

6.6.2 US

6.6.3 Canada

6.6.4 Mexico

7 Europe

7.1 Europe Market Size (2020-2031)

7.2 Europe Key Players Revenue in 2024

7.3 Europe Inhalation CDMO Market Size by Type (2020-2031)

7.4 Europe Inhalation CDMO Market Size by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Inhalation CDMO Market Size by Country

7.6.1 Europe Revenue Trends by Country

7.6.2 Germany

7.6.3 France

7.6.4 U.K.

7.6.5 Italy

7.6.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2020-2031)

8.2 Asia-Pacific Key Players Revenue in 2024

8.3 Asia-Pacific Inhalation CDMO Market Size by Type (2020-2031)

8.4 Asia-Pacific Inhalation CDMO Market Size by Application (2020-2031)

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Asia-Pacific Inhalation CDMO Market Size by Region

8.6.1 Asia-Pacific Revenue Trends by Region

8.7 China

8.8 Japan

8.9 South Korea

8.10 Australia

8.11 India

8.12 Southeast Asia

8.12.1 Indonesia

8.12.2 Vietnam

8.12.3 Malaysia

8.12.4 Philippines

8.12.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2020-2031)

9.2 Central and South America Key Players Revenue in 2024

9.3 Central and South America Inhalation CDMO Market Size by Type (2020-2031)

9.4 Central and South America Inhalation CDMO Market Size by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Inhalation CDMO Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2020-2031)

10.2 Middle East and Africa Key Players Revenue in 2024

10.3 Middle East and Africa Inhalation CDMO Market Size by Type (2020-2031)

10.4 Middle East and Africa Inhalation CDMO Market Size by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Inhalation CDMO Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Israel

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Lonza

11.1.1 Lonza Corporation Information

11.1.2 Lonza Business Overview

11.1.3 Lonza Inhalation CDMO Product Features and Attributes

11.1.4 Lonza Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.1.5 Lonza Inhalation CDMO Revenue by Product in 2024

11.1.6 Lonza Inhalation CDMO Revenue by Application in 2024

11.1.7 Lonza Inhalation CDMO Revenue by Geographic Area in 2024

11.1.8 Lonza Inhalation CDMO SWOT Analysis

11.1.9 Lonza Recent Developments

11.2 Vectura

11.2.1 Vectura Corporation Information

11.2.2 Vectura Business Overview

11.2.3 Vectura Inhalation CDMO Product Features and Attributes

11.2.4 Vectura Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.2.5 Vectura Inhalation CDMO Revenue by Product in 2024

11.2.6 Vectura Inhalation CDMO Revenue by Application in 2024

11.2.7 Vectura Inhalation CDMO Revenue by Geographic Area in 2024

11.2.8 Vectura Inhalation CDMO SWOT Analysis

11.2.9 Vectura Recent Developments

11.3 Iconovo

11.3.1 Iconovo Corporation Information

11.3.2 Iconovo Business Overview

11.3.3 Iconovo Inhalation CDMO Product Features and Attributes

11.3.4 Iconovo Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.3.5 Iconovo Inhalation CDMO Revenue by Product in 2024

11.3.6 Iconovo Inhalation CDMO Revenue by Application in 2024

11.3.7 Iconovo Inhalation CDMO Revenue by Geographic Area in 2024

11.3.8 Iconovo Inhalation CDMO SWOT Analysis

11.3.9 Iconovo Recent Developments

11.4 CritiTech

11.4.1 CritiTech Corporation Information

11.4.2 CritiTech Business Overview

11.4.3 CritiTech Inhalation CDMO Product Features and Attributes

11.4.4 CritiTech Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.4.5 CritiTech Inhalation CDMO Revenue by Product in 2024

11.4.6 CritiTech Inhalation CDMO Revenue by Application in 2024

11.4.7 CritiTech Inhalation CDMO Revenue by Geographic Area in 2024

11.4.8 CritiTech Inhalation CDMO SWOT Analysis

11.4.9 CritiTech Recent Developments

11.5 Hovione

11.5.1 Hovione Corporation Information

11.5.2 Hovione Business Overview

11.5.3 Hovione Inhalation CDMO Product Features and Attributes

11.5.4 Hovione Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.5.5 Hovione Inhalation CDMO Revenue by Product in 2024

11.5.6 Hovione Inhalation CDMO Revenue by Application in 2024

11.5.7 Hovione Inhalation CDMO Revenue by Geographic Area in 2024

11.5.8 Hovione Inhalation CDMO SWOT Analysis

11.5.9 Hovione Recent Developments

11.6 Recipharm

11.6.1 Recipharm Corporation Information

11.6.2 Recipharm Business Overview

11.6.3 Recipharm Inhalation CDMO Product Features and Attributes

11.6.4 Recipharm Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.6.5 Recipharm Recent Developments

11.7 Aptar Pharma

11.7.1 Aptar Pharma Corporation Information

11.7.2 Aptar Pharma Business Overview

11.7.3 Aptar Pharma Inhalation CDMO Product Features and Attributes

11.7.4 Aptar Pharma Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.7.5 Aptar Pharma Recent Developments

11.8 Kindeva

11.8.1 Kindeva Corporation Information

11.8.2 Kindeva Business Overview

11.8.3 Kindeva Inhalation CDMO Product Features and Attributes

11.8.4 Kindeva Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.8.5 Kindeva Recent Developments

11.9 Sanner

11.9.1 Sanner Corporation Information

11.9.2 Sanner Business Overview

11.9.3 Sanner Inhalation CDMO Product Features and Attributes

11.9.4 Sanner Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.9.5 Sanner Recent Developments

11.10 Particle Sciences

11.10.1 Particle Sciences Corporation Information

11.10.2 Particle Sciences Business Overview

11.10.3 Particle Sciences Inhalation CDMO Product Features and Attributes

11.10.4 Particle Sciences Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.10.5 Company Ten Recent Developments

11.11 Experic

11.11.1 Experic Corporation Information

11.11.2 Experic Business Overview

11.11.3 Experic Inhalation CDMO Product Features and Attributes

11.11.4 Experic Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.11.5 Experic Recent Developments

11.12 Enteris Biopharma

11.12.1 Enteris Biopharma Corporation Information

11.12.2 Enteris Biopharma Business Overview

11.12.3 Enteris Biopharma Inhalation CDMO Product Features and Attributes

11.12.4 Enteris Biopharma Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.12.5 Enteris Biopharma Recent Developments

11.13 Catalent

11.13.1 Catalent Corporation Information

11.13.2 Catalent Business Overview

11.13.3 Catalent Inhalation CDMO Product Features and Attributes

11.13.4 Catalent Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.13.5 Catalent Recent Developments

11.14 HCmed

11.14.1 HCmed Corporation Information

11.14.2 HCmed Business Overview

11.14.3 HCmed Inhalation CDMO Product Features and Attributes

11.14.4 HCmed Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.14.5 HCmed Recent Developments

11.15 Ritedose

11.15.1 Ritedose Corporation Information

11.15.2 Ritedose Business Overview

11.15.3 Ritedose Inhalation CDMO Product Features and Attributes

11.15.4 Ritedose Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.15.5 Ritedose Recent Developments

11.16 Bespak

11.16.1 Bespak Corporation Information

11.16.2 Bespak Business Overview

11.16.3 Bespak Inhalation CDMO Product Features and Attributes

11.16.4 Bespak Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.16.5 Bespak Recent Developments

11.17 Proveris

11.17.1 Proveris Corporation Information

11.17.2 Proveris Business Overview

11.17.3 Proveris Inhalation CDMO Product Features and Attributes

11.17.4 Proveris Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.17.5 Proveris Recent Developments

11.18 Bend Bioscience

11.18.1 Bend Bioscience Corporation Information

11.18.2 Bend Bioscience Business Overview

11.18.3 Bend Bioscience Inhalation CDMO Product Features and Attributes

11.18.4 Bend Bioscience Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.18.5 Bend Bioscience Recent Developments

11.19 Renejix

11.19.1 Renejix Corporation Information

11.19.2 Renejix Business Overview

11.19.3 Renejix Inhalation CDMO Product Features and Attributes

11.19.4 Renejix Inhalation CDMO Revenue and Gross Margin (2020-2025)

11.19.5 Renejix Recent Developments

12 Inhalation CDMOIndustry Chain Analysis

12.1 Inhalation CDMO Industry Chain

12.2 Upstream Analysis

12.2.1 Upstream Key Suppliers

12.3 Middlestream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Inhalation CDMO Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Inhalation CDMO Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Inhalation CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Inhalation CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Inhalation CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Inhalation CDMO Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Inhalation CDMO Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Inhalation CDMO Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Inhalation CDMO Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Inhalation CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inhalation CDMO as of 2024)

Table 11. Global Inhalation CDMO Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Inhalation CDMO Companies Headquarters

Table 13. Global Inhalation CDMO Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Inhalation CDMO Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Inhalation CDMO Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Inhalation CDMO Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Inhalation CDMO Revenue by Application (2026-2031) & (US$ Million)

Table 21. Inhalation CDMO High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Inhalation CDMO Growth Accelerators and Market Barriers

Table 25. North America Inhalation CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Inhalation CDMO Growth Accelerators and Market Barriers

Table 27. Europe Inhalation CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Inhalation CDMO Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Inhalation CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Inhalation CDMO Investment Opportunities and Key Challenges

Table 31. Central and South America Inhalation CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Inhalation CDMO Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Inhalation CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Lonza Corporation Information

Table 35. Lonza Description and Major Businesses

Table 36. Lonza Product Features and Attributes

Table 37. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Lonza Revenue Proportion by Product in 2024

Table 39. Lonza Revenue Proportion by Application in 2024

Table 40. Lonza Revenue Proportion by Geographic Area in 2024

Table 41. Lonza Inhalation CDMO SWOT Analysis

Table 42. Lonza Recent Developments

Table 43. Vectura Corporation Information

Table 44. Vectura Description and Major Businesses

Table 45. Vectura Product Features and Attributes

Table 46. Vectura Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Vectura Revenue Proportion by Product in 2024

Table 48. Vectura Revenue Proportion by Application in 2024

Table 49. Vectura Revenue Proportion by Geographic Area in 2024

Table 50. Vectura Inhalation CDMO SWOT Analysis

Table 51. Vectura Recent Developments

Table 52. Iconovo Corporation Information

Table 53. Iconovo Description and Major Businesses

Table 54. Iconovo Product Features and Attributes

Table 55. Iconovo Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Iconovo Revenue Proportion by Product in 2024

Table 57. Iconovo Revenue Proportion by Application in 2024

Table 58. Iconovo Revenue Proportion by Geographic Area in 2024

Table 59. Iconovo Inhalation CDMO SWOT Analysis

Table 60. Iconovo Recent Developments

Table 61. CritiTech Corporation Information

Table 62. CritiTech Description and Major Businesses

Table 63. CritiTech Product Features and Attributes

Table 64. CritiTech Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. CritiTech Revenue Proportion by Product in 2024

Table 66. CritiTech Revenue Proportion by Application in 2024

Table 67. CritiTech Revenue Proportion by Geographic Area in 2024

Table 68. CritiTech Inhalation CDMO SWOT Analysis

Table 69. CritiTech Recent Developments

Table 70. Hovione Corporation Information

Table 71. Hovione Description and Major Businesses

Table 72. Hovione Product Features and Attributes

Table 73. Hovione Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Hovione Revenue Proportion by Product in 2024

Table 75. Hovione Revenue Proportion by Application in 2024

Table 76. Hovione Revenue Proportion by Geographic Area in 2024

Table 77. Hovione Inhalation CDMO SWOT Analysis

Table 78. Hovione Recent Developments

Table 79. Recipharm Corporation Information

Table 80. Recipharm Description and Major Businesses

Table 81. Recipharm Product Features and Attributes

Table 82. Recipharm Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. Recipharm Recent Developments

Table 84. Aptar Pharma Corporation Information

Table 85. Aptar Pharma Description and Major Businesses

Table 86. Aptar Pharma Product Features and Attributes

Table 87. Aptar Pharma Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. Aptar Pharma Recent Developments

Table 89. Kindeva Corporation Information

Table 90. Kindeva Description and Major Businesses

Table 91. Kindeva Product Features and Attributes

Table 92. Kindeva Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Kindeva Recent Developments

Table 94. Sanner Corporation Information

Table 95. Sanner Description and Major Businesses

Table 96. Sanner Product Features and Attributes

Table 97. Sanner Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Sanner Recent Developments

Table 99. Particle Sciences Corporation Information

Table 100. Particle Sciences Description and Major Businesses

Table 101. Particle Sciences Product Features and Attributes

Table 102. Particle Sciences Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. Particle Sciences Recent Developments

Table 104. Experic Corporation Information

Table 105. Experic Description and Major Businesses

Table 106. Experic Product Features and Attributes

Table 107. Experic Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. Experic Recent Developments

Table 109. Enteris Biopharma Corporation Information

Table 110. Enteris Biopharma Description and Major Businesses

Table 111. Enteris Biopharma Product Features and Attributes

Table 112. Enteris Biopharma Revenue (US$ Million) and Gross Margin (2020-2025)

Table 113. Enteris Biopharma Recent Developments

Table 114. Catalent Corporation Information

Table 115. Catalent Description and Major Businesses

Table 116. Catalent Product Features and Attributes

Table 117. Catalent Revenue (US$ Million) and Gross Margin (2020-2025)

Table 118. Catalent Recent Developments

Table 119. HCmed Corporation Information

Table 120. HCmed Description and Major Businesses

Table 121. HCmed Product Features and Attributes

Table 122. HCmed Revenue (US$ Million) and Gross Margin (2020-2025)

Table 123. HCmed Recent Developments

Table 124. Ritedose Corporation Information

Table 125. Ritedose Description and Major Businesses

Table 126. Ritedose Product Features and Attributes

Table 127. Ritedose Revenue (US$ Million) and Gross Margin (2020-2025)

Table 128. Ritedose Recent Developments

Table 129. Bespak Corporation Information

Table 130. Bespak Description and Major Businesses

Table 131. Bespak Product Features and Attributes

Table 132. Bespak Revenue (US$ Million) and Gross Margin (2020-2025)

Table 133. Bespak Recent Developments

Table 134. Proveris Corporation Information

Table 135. Proveris Description and Major Businesses

Table 136. Proveris Product Features and Attributes

Table 137. Proveris Revenue (US$ Million) and Gross Margin (2020-2025)

Table 138. Proveris Recent Developments

Table 139. Bend Bioscience Corporation Information

Table 140. Bend Bioscience Description and Major Businesses

Table 141. Bend Bioscience Product Features and Attributes

Table 142. Bend Bioscience Revenue (US$ Million) and Gross Margin (2020-2025)

Table 143. Bend Bioscience Recent Developments

Table 144. Renejix Corporation Information

Table 145. Renejix Description and Major Businesses

Table 146. Renejix Product Features and Attributes

Table 147. Renejix Revenue (US$ Million) and Gross Margin (2020-2025)

Table 148. Renejix Recent Developments

Table 149. Raw Materials Key Suppliers

Table 150. Distributors List

Table 151. Market Trends and Market Evolution

Table 152. Market Drivers and Opportunities

Table 153. Market Challenges, Risks, and Restraints

Table 154. Research Programs/Design for This Report

Table 155. Key Data Information from Secondary Sources

Table 156. Key Data Information from Primary Sources

List of Figures

Figure 1. Inhalation CDMO Product Picture

Figure 2. Global Inhalation CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Metered Dose Inhalers (MDIs) Product Picture

Figure 4. Dry Powder Inhalers (DPIs) Product Picture

Figure 5. Soft Mist Inhalers (SMIs) Product Picture

Figure 6. Others Product Picture

Figure 7. Global Inhalation CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 8. Commercial

Figure 9. Academic Research

Figure 10. Others

Figure 11. Inhalation CDMO Report Years Considered

Figure 12. Global Inhalation CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 14. Global Inhalation CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global Inhalation CDMO Revenue Market Share by Region (2020-2031)

Figure 16. Global Inhalation CDMO Revenue Market Share Ranking (2024)

Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 18. Metered Dose Inhalers (MDIs) Revenue Market Share by Player in 2024

Figure 19. Dry Powder Inhalers (DPIs) Revenue Market Share by Player in 2024

Figure 20. Soft Mist Inhalers (SMIs) Revenue Market Share by Player in 2024

Figure 21. Others Revenue Market Share by Player in 2024

Figure 22. Global Inhalation CDMO Revenue Market Share by Type (2020-2031)

Figure 23. Global Inhalation CDMO Revenue Market Share by Application (2020-2031)

Figure 24. North America Inhalation CDMO Revenue YoY (2020-2031) & (US$ Million)

Figure 25. North America Top 5 Players Inhalation CDMO Revenue (US$ Million) in 2024

Figure 26. North America Inhalation CDMO Revenue (US$ Million) by Type (2020 - 2031)

Figure 27. North America Inhalation CDMO Revenue (US$ Million) by Application (2020-2031)

Figure 28. US Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 29. Canada Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 30. Mexico Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 31. Europe Inhalation CDMO Revenue YoY (2020-2031) & (US$ Million)

Figure 32. Europe Top 5 Players Inhalation CDMO Revenue (US$ Million) in 2024

Figure 33. Europe Inhalation CDMO Revenue (US$ Million) by Type (2020-2031)

Figure 34. Europe Inhalation CDMO Revenue (US$ Million) by Application (2020-2031)

Figure 35. Germany Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 36. France Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 37. U.K. Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 38. Italy Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 39. Russia Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Inhalation CDMO Revenue YoY (2020-2031) & (US$ Million)

Figure 41. Asia-Pacific Top 8 Players Inhalation CDMO Revenue (US$ Million) in 2024

Figure 42. Asia-Pacific Inhalation CDMO Revenue (US$ Million) by Type (2020-2031)

Figure 43. Asia-Pacific Inhalation CDMO Revenue (US$ Million) by Application (2020-2031)

Figure 44. Indonesia Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 45. Japan Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 46. South Korea Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 47. Australia Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 48. India Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 49. Indonesia Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 50. Vietnam Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 51. Malaysia Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 52. Philippines Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 53. Singapore Inhalation CDMO Revenue (2020-2031) & (US$ Million)

Figure 54. Central and South America Inhalation CDMO Revenue YoY (2020-2031) & (US$ Million)

Figure 55. Central and South America Top 5 Players Inhalation CDMO Revenue (US$ Million) in 2024

Figure 56. Central and South America Inhalation CDMO Revenue (US$ Million) by Type (2020-2031)

Figure 57. Central and South America Inhalation CDMO Revenue (US$ Million) by Application (2020-2031)

Figure 58. Brazil Inhalation CDMO Revenue (2020-2025) & (US$ Million)

Figure 59. Argentina Inhalation CDMO Revenue (2020-2025) & (US$ Million)

Figure 60. Middle East and Africa Inhalation CDMO Revenue YoY (2020-2031) & (US$ Million)

Figure 61. Middle East and Africa Top 5 Players Inhalation CDMO Revenue (US$ Million) in 2024

Figure 62. South America Inhalation CDMO Revenue (US$ Million) by Type (2020-2031)

Figure 63. Middle East and Africa Inhalation CDMO Revenue (US$ Million) by Application (2020-2031)

Figure 64. GCC Countries Inhalation CDMO Revenue (2020-2025) & (US$ Million)

Figure 65. Israel Inhalation CDMO Revenue (2020-2025) & (US$ Million)

Figure 66. Egypt Inhalation CDMO Revenue (2020-2025) & (US$ Million)

Figure 67. South Africa Inhalation CDMO Revenue (2020-2025) & (US$ Million)

Figure 68. Inhalation CDMO Industry Chain Mapping

Figure 69. Channels of Distribution (Direct Vs Distribution)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-14O17929

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Ozone Medical Instrument Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28E19710

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Knotless Tissue-Closure Device Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-11A18018

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Medical Device SPD (Supply-Processing-Distribution) Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-13W20069

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Inhalation CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: October 2025

Report Code: QYRE-Auto-24J17966

Global Inhalation CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031

FEATURED COMPANIES

Inhalation CDMO Market Size

Inhalation CDMO Market

Report Includes:

Scope of Inhalation CDMO Market Report

Chapter Outline

FAQ for this report

How fast is Inhalation CDMO Market growing?

What is the Inhalation CDMO Market size in 2031?

Who are the main players in the Inhalation CDMO Market report?

What are the Application segmentation covered in the Inhalation CDMO Market report?

What are the Type segmentation covered in the Inhalation CDMO Market report?

FEATURED COMPANIES

RELATED REPORTS